We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Commercial Fully Automated Procalcitonin Immunoassay Compared

By LabMedica International staff writers
Posted on 04 Dec 2018
Print article
Image: The ARCHITECT B.R.A.H.M.S PCT assay, which is a two-step immunoassay using chemiluminescent microparticle immunoassay (CMIA) technology (Photo courtesy of Abbott Laboratories).
Image: The ARCHITECT B.R.A.H.M.S PCT assay, which is a two-step immunoassay using chemiluminescent microparticle immunoassay (CMIA) technology (Photo courtesy of Abbott Laboratories).
Procalcitonin (PCT), a 13-kDa peptide precursor of calcitonin, has gained widespread acceptance as an early and specific biomarker for the presence of systemic bacterial infection. In particular, PCT monitoring has demonstrated value in guiding antibiotic use for bacterial infections.

Based on high plasma levels of PCT during systemic bacterial and fungal infections that decrease on recovery and low concentrations during infections of viral origin or nonspecific causes, the use of PCT assays can be used to assist the clinical management of different patient groups in a range of clinical settings.

An international team of scientists working with the Abbott Laboratories (Abbott Park, IL, USA) using de-identified 1,116 plasma or serum samples from patients tested at nine clinical laboratories in Australia, France, Germany, Italy, South Africa, Turkey, Vietnam and Wales. Plasma or serum samples were tested either fresh or following storage of the serum fraction at 2–8 °C for a maximum of 24 hours.

The team evaluated the ARCHITECT B.R.A.H.M.S PCT assay, which is a two-step immunoassay using chemiluminescent microparticle immunoassay (CMIA) technology, with a 29-minute assay completion time. The ARCHITECT B.R.A.H.M.S PCT assay was evaluated on Abbott Laboratories’ ARCHITECT i2000SR immunoanalyzers. The ARCHITECT B.R.A.H.M.S PCT assay was compared with the Roche Cobas (Basel, Switzerland), Diasorin LIAISON (Saluggia, Italy); bioMérieux VIDAS (‎Marcy-l'Étoile, France), and widely accepted B.R.A.H.M.S Kryptor systems (Hennigsdorf, Germany).

The scientists reported that using Deming regression analysis of the plasma or serum samples with PCT results detected across a dynamic assay range of 0.02–100 μg/L using the ARCHITECT B.R.A.H.M.S PCT assay yielded results of r = 0.989 versus. Roche Cobas, r = 0.986 versus Kryptor B.R.A.H.M.S, r = 0.987 versus BioMérieux VIDAS and r = 0.972 versus Diasorin LIAISON respectively. Concordance at cut-offs of 0.25 μg/L and 0.50 μg/L were 96.9% and 98.1% with Roche Cobas, 95.4% and 96.1% with B.R.A.H.M.S Kryptor, 93.8% and 98.4% with bioMérieux VIDAS, and 92.7% and 93.9% with Diasorin LIAISON.

The authors concluded that independent observations at nine different clinical laboratory sites confirmed the analytical characteristics of the ARCHITECT B.R.A.H.M.S PCT immunoassay. Compared with other assays, ARCHITECT B.R.A.H.M.S PCT offers excellent precision and low-end sensitivity. The study was published on November 9, 2018, in the journal Practical Laboratory Medicine.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.